Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Debt / NOTE 3.250%11/0
-
Market price (% of par)
-
102.01%
-
Total 13F principal
-
$218,794,473
-
Principal change
-
-$11,020,527
-
Total reported market value
-
$223,386,639
-
Number of holders
-
21
-
Value change
-
-$11,047,671
-
Number of buys
-
3
-
Number of sells
-
8
Institutional Holders of THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 as of Q1 2021
As of 31 Mar 2021,
THERAVANCE BIOPHARMA INC - NOTE 3.250%11/0 was held by
21 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$218,794,473
in principal (par value) of the bond.
The largest 10 bondholders included
CITADEL ADVISORS LLC, Farallon Capital Management, L.L.C., BAUPOST GROUP LLC/MA, WOLVERINE ASSET MANAGEMENT LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, Shaolin Capital Management LLC, OAKTREE CAPITAL MANAGEMENT LP, TENOR CAPITAL MANAGEMENT Co., L.P., ZAZOVE ASSOCIATES LLC, and MORGAN STANLEY.
This page lists
21
institutional bondholders reporting positions
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.